Global Hip Tendinitis Market Growth (Status and Outlook) 2023-2029

Global Hip Tendinitis Market Growth (Status and Outlook) 2023-2029

The global Hip Tendinitis market size is projected to grow from US$ 282.2 million in 2022 to US$ 402.6 million in 2029; it is expected to grow at a CAGR of 5.2% from 2023 to 2029.

United States market for Hip Tendinitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Hip Tendinitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Hip Tendinitis is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Hip Tendinitis players cover Almatica Pharma, AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Merck & Co., Pfizer, Abbott, GlaxoSmithKline and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Hip tendinitis is an uncomfortable inflammatory condition when a tendon in the hip becomes iritated or inflamed. Other names for it include hip tendonitis and hip flexor tendonitis. The rapidly increasing rate of the senior population worldwide and growing sports activities are primarily increasing the demand for hip tendonitis treatment.

LPI (LP Information)' newest research report, the “Hip Tendinitis Industry Forecast” looks at past sales and reviews total world Hip Tendinitis sales in 2022, providing a comprehensive analysis by region and market sector of projected Hip Tendinitis sales for 2023 through 2029. With Hip Tendinitis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hip Tendinitis industry.

This Insight Report provides a comprehensive analysis of the global Hip Tendinitis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hip Tendinitis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hip Tendinitis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hip Tendinitis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hip Tendinitis.

This report presents a comprehensive overview, market shares, and growth opportunities of Hip Tendinitis market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Internal Snapping Hip
External Snapping Hip
Intra-articular Snapping Hip

Segmentation by application
Hospitals & Clinics
Medical Research Centers
Academic Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Almatica Pharma
AstraZeneca
Bayer
Boehringer Ingelheim Pharmaceuticals
Merck & Co.
Pfizer
Abbott
GlaxoSmithKline
Teva Pharmaceuticals
Lupin Pharmaceuticals
Geri-Care Pharmaceuticals
Perrigo Company

Please note: the online download version of this report is for a global site license.